Relapsing Remitting Multiple Sclerosis Clinical Trials Pipeline Analysis: 28+ Companies are working to improve the Treatment of Space

DelveInsight's, "Relapsing Remitting Multiple Sclerosis Pipeline Insight 2023" report provides comprehensive insights about 28+ companies and 30+ pipeline drugs in the Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing Remitting Multiple Sclerosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Relapsing Remitting Multiple Sclerosis Emerging drugs, the Relapsing Remitting Multiple Sclerosis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Relapsing Remitting Multiple Sclerosis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

In the Relapsing Remitting Multiple Sclerosis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Relapsing Remitting Multiple Sclerosis clinical trials studies, Relapsing Remitting Multiple Sclerosis NDA approvals (if any), and product development activities comprising the technology, Relapsing Remitting Multiple Sclerosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from the Relapsing Remitting Multiple Sclerosis Pipeline Report

• DelveInsight's Relapsing Remitting Multiple Sclerosis Pipeline analysis depicts a robust space with 28+ active players working to develop 30+ pipeline treatment therapies.

• The leading Relapsing Remitting Multiple Sclerosis Companies includes Sanofi, RemeGen, RedHill Biopharma, Polpharma Biologics, Pipeline Therapeutics, Oryzon Genomics, Novartis, Merck, Medsenic, Mapi Pharma, InnoCare Pharma, Immunic, Immune Response BioPharma, HuniLife Biotechnology, GlaxoSmithKline, and others.

• Promising Relapsing Remitting Multiple Sclerosis Pipeline Therapies includes Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others

• The Relapsing Remitting Multiple Sclerosis companies and academics are working to assess challenges and seek opportunities that could influence Relapsing Remitting multiple sclerosis R&D. The Relapsing Remitting Multiple Sclerosis pipeline therapies under development are focused on novel approaches to treat/improve Relapsing Remitting multiple sclerosis.

Request a sample and discover the recent breakthroughs happening in the Relapsing Remitting Multiple Sclerosis Pipeline landscape @ Relapsing Remitting Multiple Sclerosis Pipeline Outlook- https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Relapsing Remitting Multiple Sclerosis Overview
Multiple sclerosis (MS) is the most common neurological disorder in young adults, with symptoms usually occurring between the ages of 20 and 40 years. MS attacks the axons of the central nervous system, which are protected by myelin, commonly known as white matter. Relapsing-remitting MS: the most common form, affecting about 85% of MS patients. It is marked by flare-ups (relapses or exacerbations) of symptoms followed by periods of remission, when symptoms improve or disappear. The term multiple sclerosis refers to the distinctive areas of scar tissue (sclerosis - also called plaques or lesions) that result from the attack on myelin by the immune system. These plaques are visible using magnetic resonance imaging in the white and/or gray matter of people who have MS. Plaques can be as small as a pinhead or as large as a golf ball.

Recent Developmental Activities in the Relapsing Remitting Multiple Sclerosis Treatment Landscape

• In March 2022, Pipeline Therapeutics is set to commence the Phase Ib/IIa clinical trial of its lead programme, PIPE-307, to treat relapsing-remitting multiple sclerosis (RRMS) patients. The move comes after the company obtained clearance for its investigational new drug application from the US Food and Drug Administration (FDA) to launch the trial. An oral, selective muscarinic M1 receptor antagonist, PIPE-307, is being developed for restoring myelin to treat MS.

• In July 2021, InnoCare received $125 million upfront in return for sharing rights to orelabrutinib, an orally-active BTK drug that can cross the blood-brain barrier and penetrate the central nervous system. It is currently in a phase 2 trial for relapsing-remitting multiple sclerosis (RRMS). The deal was back-ended with up to $812.5 million in milestone payments if the drug reaches development, regulatory and commercial milestones, and royalties on any future sales.

For further information, refer to the detailed Relapsing Remitting Multiple Sclerosis Drugs Launch, Relapsing Remitting Multiple Sclerosis Developmental Activities, and Relapsing Remitting Multiple Sclerosis News, click here for Relapsing Remitting Multiple Sclerosis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Relapsing Remitting Multiple Sclerosis Emerging Drugs Profile

• Natalizumab: Polpharma Biologics
Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. Natalizumab is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood-brain barrier. In July 2022, Polpharma Biologics announced that the US Food and Drug Administration (FDA) accepted the first-ever Biologics License Application (BLA) for natalizumab, a proposed biosimilar to Tysabri, filed by their collaboration partner Sandoz. The application is for an intravenous (IV) route of administration, with the same dosing regimen, presentation and indication as the reference medicine, Tysabri (natalizumab) - a monotherapy for adult patients with relapsing-remitting multiple sclerosis (RRMS) and adults with moderately-to-severely active Crohn's disease. A Marketing Approval Application (MAA) for the proposed biosimilar natalizumab was also accepted by the European Medicines Agency (EMA) on 14 July 2022.

• Remibrutinib: Novartis
Remibrutinib (LOU064) is a highly selective and potent covalent BTK inhibitor with a potential best-in-class profile and has shown favorable safety based on clinical data established to date. BTK inhibitors are a novel class of therapies that target B-cells and other innate immune cells and prevent inflammation and potentially disease progression in MS.

• IMU-838: Immunic AG
Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. Bolstered by excellent clinical data from the phase II EMPhASIS trial, Immunic believed that vidofludimus calcium has the potential to demonstrate medically important advantages compared with other treatments, particularly for the early treatment of RMS patients, due to its placebo like safety profile and its robust anti-inflammatory and neuroprotective properties.

Relapsing Remitting Multiple Sclerosis Pipeline Therapeutics Assessment
There are approx. 28+ key companies which are developing the therapies for Relapsing Remitting multiple sclerosis. The companies which have their Relapsing Remitting multiple sclerosis drug candidates in the most advanced stage, i.e. Preregistration include, Polpharma Biologics.

Find out more about the Relapsing Remitting Multiple Sclerosis Pipeline Segmentation, Therapeutics Assessment, and Relapsing Remitting Multiple Sclerosis Emerging Drugs @ Relapsing Remitting Multiple Sclerosis Treatment Landscape- https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Relapsing Remitting Multiple Sclerosis Pipeline Report

• Coverage- Global

• Relapsing Remitting Multiple Sclerosis Companies- Sanofi, RemeGen, RedHill Biopharma, Polpharma Biologics, Pipeline Therapeutics, Oryzon Genomics, Novartis, Merck, Medsenic, Mapi Pharma, InnoCare Pharma, Immunic, Immune Response BioPharma, HuniLife Biotechnology, GlaxoSmithKline, and others.

• Relapsing Remitting Multiple Sclerosis Pipeline Therapies includes Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others

• Relapsing Remitting Multiple Sclerosis Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Relapsing Remitting Multiple Sclerosis Pipeline Companies and Therapies, click here @ Relapsing Remitting Multiple Sclerosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Relapsing Remitting multiple sclerosis : Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Relapsing Remitting multiple sclerosis - DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Natalizumab: Polpharma Biologics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Orelabrutinib: InnoCare Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. HuL001: HuniLife Biotechnology
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Relapsing Remitting multiple sclerosis - Collaborations Assessment- Licensing / Partnering / Funding
18. Relapsing Remitting multiple sclerosis - Unmet Needs
19. Relapsing Remitting multiple sclerosis - Market Drivers and Barriers
20. Appendix

Got Queries? Find out the related information on Relapsing Remitting Multiple Sclerosis Mergers and acquisitions, Relapsing Remitting Multiple Sclerosis Licensing Activities @ Relapsing Remitting Multiple Sclerosis Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/out-licensing-opportunity

This release was published on openPR.